Notice: Constant automattic\jetpack\extensions\social_previews\FEATURE_NAME already defined in /home2/theprkho/public_html/thepharmatimes.in/wp-content/plugins/jetpack/extensions/blocks/social-previews/social-previews.php on line 14
Venus gets Indonesian GMP certification for its Baddi unit - The Pharma Times | Pharma & Health Care News Portal
Categories: Accreditation

Venus gets Indonesian GMP certification for its Baddi unit

Indonesia offers a growing market for oncology products with cancer being the sixth most leading cause of death in that country

  Chandigarh  February 6, 2014 : – Drug major  today said it has got good manufacturing practices () certification from Indonesia for its unit located at Baddi in Himachal Pradesh.
    
Indonesian National Agency for Drug and Food Control (NADFC) granted the certification after an extensive review and audit of the facility, said a company statement issued here today.
    
“Such recognitions for our manufacturing facilities and consistent quality of our procedures and practices open tremendous opportunities for us to expand our product portfolio across the globe… This GMP approval will soon pave the way for marketing authorisations from Indonesia,” said Manu Chaudhary, Joint Managing Director, Venus Remedies Ltd.
    
Indonesia offers a growing market for  products with cancer being the sixth most leading cause of death in that country after infectious diseases, cardiovascular diseases, traffic accidents, nutritional deficiency and congenital diseases.
    
With a sizable population of 234 million, with a rapidly expanding middle class, Indonesia is poised to emerge as a key market of growth for the healthcare and pharmaceutical industry.
    
Currently worth $4.5 billion, Indonesia’s pharmaceutical market is expanding at an annual rate of 12.5 per cent.
    
“A potential market for our oncology product line, Indonesia records 170-190 new cancer cases annually in a population of every 1 lakh. The Indonesian oncology market, worth $88.58 million in 2013, is expected to grow at 10 per cent.
    
“We will commercially launch our products in Indonesia by the middle of this year and are projected to generate revenue of $1 million in the first year itself. With the launch of our oncology products in Indonesia, we aim at capturing the maximum share in the country’s pharmaceutical market,” said company’s CFO, Dheeraj Aggarwal.
    
The pharma major has three manufacturing units – in Panchkula (Haryana), Baddi (HP) and Werne (Germany). It also has 11 overseas marketing offices, including a presence in the US and Germany.- Business standard  

The Pharma Times News Bureau

Recent Posts

Fortis Hospital, Bannerghatta Road Launches dedicated Parkinson’s Disease and Deep Brain Stimulation Clinic

-  This specialized division empowers patients with neurological disorders to reclaim their mobility through a…

2 days ago

Milestone set in Indian Medical History – SSI Mantra Surgical Robotic System Performs the First-Ever Successful Surgery on One-Year-Old Infant

SSI Mantra Robotic System performs a successful urology procedure on a one-year-old infant with a…

4 days ago

Manipal Hospital Ghaziabad organises Fire Safety Training to Enhance Emergency Response

Ghaziabad, April 22, 2024: In order to strengthen the safety and wellbeing of people, Manipal Hospital…

2 weeks ago

Professor Dr Robert Zeiser receives DKMS Mechtild Harf Science Award 2024

DKMS EMPHASIZES ITS COMMITMENT TO BLOOD CANCER RESEARCH, SUPPORTS YOUNG SCIENTISTS, AND RECOGNIZES OUTSTANDING RESEARCH…

2 weeks ago

Dr. Reddy’s launches drug-free migraine management device Nerivio® in Europe following successful launch in India

Dr. Reddy's has launched Nerivio® in Germany through its step-down subsidiary betapharm To be followed…

3 weeks ago

Ankura Hospital Doctors perform a successful Complex Lung Surgery on a 4-month-old Infant

 Hyderabad, April 13, 2024: Ankura Hospital for Women and Children is proud to announce a remarkable medical…

3 weeks ago